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Edited by Jesus AvilaAbstract Two melatonin receptors (MT1 and MT2) have been
cloned. A third melatonin binding site, MT3, is known with
remarkable and distinct pharmacological properties. We previ-
ously reported the puriﬁcation of MT3 and identiﬁed it as the
enzyme dihydronicotinamide riboside:quinone reductase 2
(NQO2). To investigate the relationship between NQO2 and
MT3, we generated a NQO2
/ mouse strain. These mice no
longer present MT3 binding sites as measured with 2-[
125I]-iodo,
5-methoxycarbonylamino-N-acetyltryptamine, the speciﬁc MT3
radioligand. These data establish NQO2 as part of the MT3
binding sites in vivo and resolve the matter of the nature of the
third melatonin binding site.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Quinone reductase 11. Introduction
Melatonin is a serotonin-derived neurohormone produced in
the pineal gland that relays information about the photoperiod
to the peripheral organs for daily and seasonal physiological
regulations [1–3]. The cellular targets of melatonin have been
detected by binding studies with a speciﬁc agonist, 2-iodomela-
tonin, in numerous peripheral tissues of birds and mammals
[4], as well as in lower organisms, including plants [5]. Three
melatonin receptors have been cloned to date. Two melatonin
receptors (MT1 and MT2) have been extensively studied [6–10].
Another one, not expressed in mammals [11], the Mel1c, was
cloned from Xenopus laevis [12]. In mammals, a third binding
site has been described,MT3, initially in brain and kidney from
hamster [13] and then in diﬀerent species [14–17]. It has
remarkably diﬀerent pharmacological properties [13–17] dis-Abbreviations: QR1, quinone reductase 1; NQO2, NRH:quinone oxi-
doreductase 2; BNAH, N-benzyldihydronicotinamide; MCA-NAT,
5-methoxycarbonylamino-N-acetyltryptamine; NRH, dihydronicotin-
amide riboside
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common seven-transmembrane predicted structure and the
ability to transduce extra-cellular signals via G-protein cou-
pling [18,19]. These two receptors also share close pharmaco-
logical proﬁles [8,10], including subnanomolar aﬃnities for
melatonin and 2-iodo-melatonin.
The ligands of MT3 are speciﬁc over MT1 and MT2 and in-
clude to date 2-methoxycarbonylamino-N-acetyltryptamine
(MCA-NAT) [13], nitroindole derivatives [20] and prazosin.
Accordingly, an original ligand developed in the past for
MT3 studies, [
125I]-2-iodo, 5-methoxycarbonylamino-N-acetyl-
tryptamine (2-[125I]-MCANAT) [16], was preferentially used in
the present work. Besides its original pharmacology, MT3 dis-
plays very fast kinetics of ligand association/dissociation,
which made aﬃnity measurements diﬃcult [16,17]. We puriﬁed
this protein to homogeneity, sequenced it by mass spectrome-
try [21] and identiﬁed it as dihydronicotinamide riboside
(NRH):quinone oxidoreductase 2 (NQO2), an analog of the
detoxiﬁcation process machinery enzyme, quinone reductase
1 (QR1) [22,23]. The expression of NQO2 in naı¨ve cells led
to the MT3 pharmacology [21]. Nevertheless, despite this dem-
onstration, other studies were needed to unambiguously dem-
onstrate that this enzyme represented all the MT3 melatonin
binding sites. Among them, the construction of a mouse strain
invalidated for NQO2 gene was an essential tool for the under-
standing of this receptor. In the present work, we report that
the organs of mice deleted for NQO2 are depleted of MT3
binding sites.2. Materials and methods
2.1. Construction of the targeting vector
Genomic clones containing the murine NQO2 locus were isolated
from a 129Sv/J-BAC genomic library (Incyte Genomics) by using
probe corresponding to the murine NQO2 exon 1. The genomic organ-
ization of the locus was determined by subcloning PstI and SacI geno-
mic fragments into the pZErO-2 vector (Invitrogen, Carlsbad, USA).
The 16-kb PstI genomic insert and 4.8-kb SacI genomic insert were se-
quenced and mNQO2 sequence was generated. Both genomic clones
(containing promoter and exon 1 to intron III) were used to construct
the targeting vector. Brieﬂy, a 7.6-kb SnaBI/BstEII fragment that in-
cludes exons 1–3 and a 1.4-kb BstEII/BclI fragment that is immediately
at 3 0 of the third exon of the NQO2 gene were used to ﬂank a NEO
cassette (FRT site-MC1-Neo-FRT site-LoxP site) (as shown in Fig.
1A). A distal LoxP site has been introduced into the unique ApaI site
located into intron I in order to delete in vitro a region including
NQO2 exons 1–3 by Cre-mediated excision.ation of European Biochemical Societies.
Fig. 1. Targeted disruption of the NQO2 gene produces a null mutation. (A) Gene targeting strategy for the generation of a NQO2 KO mouse strain.
The NQO2 locus (containing the ﬁrst three exons) and the targeting construct (containing the neomycin (NEO) cassette with ﬂanking segments
homologous to the locus) are shown in schematic format. The transcriptional orientation of neomycin cassette and the NQO2 locus are delineated by
arrows. Note that homologous recombination introduces a LoxP site between exons 1 and 2 and consequently removed the ApaI site, while a SpeI
site has been introduced with the LoxP site. This SpeI site is used to screen for positive ES cell clones. The probe used in all the Southern blot analyses
is a 1.0-kb fragment located 5 0 of the targeting vector. Legend: A: ApaI site; E: EcoRV site; P: PacI site; S: SpeI site; triangle: LoxP site; double
triangle: FRT site. (B) Characterization of NQO2 targeted ES cell clones. Panel 1: PCR characterization of 3 0 targeting of the NQO2 locus. PCR
screening on 3 0 end of homologous recombination event is shown for ES cell clone #131. The 1.6 kb band signiﬁes the appropriated targeted
disruption of mNQO2 locus. Panel 2: Southern blot characterization of NQO2 targeted ES cell clones. Digestion of genomic DNA with SpeI resulted
in the following diagnostic fragment: wild type allele of 9.6-kb band, appropriate targeted disruption of the NQO2 locus of 5.7-kb band. (C) Southern
blot characterization of NQO2 exons 1, 2 and 3 Cre-mediated excised ES cell clones. Digestion of ES cell clones genomic DNA by EcoRV/PacI
resulted in the following diagnostic fragment: wild type band of 8.4-kb, KO band of 6.4-kb. The absence of 8.4-kb band signiﬁed the generation of the
NQO2 cells, while a 6.4-kb revealed the presence of a NQO2 KO allele. (D) Southern blot characterization of NQO2 exons 1, 2 and 3 Cre-mediated
excised events. Digestion of tail genomic DNA by EcoRV/PacI resulted in the following diagnostic fragment: wild type band of 8.4-kb, KO band of
6.4-kb. The absence of 8.4-kb band signiﬁed the generation of the NQO2 knockout animal, while a 6.4-kb revealed the presence of a NQO2 KO
allele.
F. Mailliet et al. / FEBS Letters 578 (2004) 116–120 1172.2. Screening of NQO2 targeted ES cell clones
129SvPas ES cells (genOway SA, Lyon) were electroporated with the
linearized targeting construct (40 lg) and selected with G418 (150 lg/
ml of active component, Life Technologies, Inc., Gibco-BRL). Homol-
ogous recombination in ES cells was assessed via PCR and Southern
blot analysis. PCR screening can be described as follows: the
GW320 primer was derived from the neomycin cassette (5 0-CAG-CGCATCGCCTTCTATCG-3 0) and the GW321 primer was derived
from NQO2 intron 3(5 0-GGAAGCGACAGTGACCTACC-30). PCR
conditions were 94 C/5 min, 35cycles of (94 C/30 sec, 57 C/1 min,
and 72 C/2 min) and then 72 C/10 min, which resulted in a 1600-
bp knockout band. Brieﬂy, for Southern blot analysis, genomic
DNA was digested with SpeI and then hybridized with a 1.0-kb inter-
nal probe; NQO2+/ clones produced a 9.6-kb wild-type band and a
118 F. Mailliet et al. / FEBS Letters 578 (2004) 116–1205.7-kb targeted band. Three clones (#131, 173 and 569) were conﬁrmed
positive for homologous recombination by both PCR and Southern
blot (Fig. 1B).
2.3. Screening for Cre-mediated excision of targeted NQO2 ES cell
clones
ES cell clone #131 isolated during the ﬁrst electroporation was
electroporated with a circular Cre-recombinase expression vector.
Cre-mediated excision in 100 selected ES clones was assessed by
Southern blot analysis. Genomic DNA was digested with EcoRV/
PacI hybridized with a 1.0-kb internal probe; in order to detect the
deletion of NQO2 intron I to intron III. NQO2 KO clones produced
a 8.4-kb wild-type and an 6.4-kb Cre-mediated deleted band (Fig.
1C).
2.4. Generation of germ line chimeras and homozygous breeding
One NQO2+/ ES cell clone was microinjected into C57BL/6 blasto-
cysts giving rise to male chimeras with a signiﬁcant ES cell contribu-
tion (as determined by an Agouti coat color). After mating with
C57BL/6 females, germ line transmission was conﬁrmed by the geno-
typing of oﬀspring tail DNA via Southern blot and PCR analysis.
F1 male and female heterozygous animals were interbred to obtain
NQO2-deﬁcient animals. Homozygous and heterozygous animals were
screened by Southern blot analysis as described in the previous section
(Fig. 1D).
2.5. Reagents
2-[125I]-MCANAT (speciﬁc activity: 2000 Ci/mmol) was custom syn-
thesized by Amersham Pharmacia Biotech (Orsay, France). Menadi-
one were obtained from Sigma (Saint Quentin Favallier, France),
whereas N-benzyldihydrobenzylnicotinamide (BNAH) was purchased
from Maybridge (Cornwell, England). All compounds were dissolved
in DMSO at a stock concentration of 10 mM before being stored at
20 C.
2.6. Biological preparations
Kidneys, and brain of male wild type (NQO2+/+), heterozygote
(NQO2+/) and knock-out (NQO2/) mice were obtained frozen at
80 C from genOway (Lyon, France). All biological sample prepara-
tions were performed at 4 C. Kidneys and brain tissues were thawed
and were resuspended in 6 vol of 50 mM Tris/HCl, pH 8.5. Tissues
were gently disrupted by 20 strokes of a glass dounce homogenizer
(A and B sizes). The homogenates were then centrifuged at
100000 · g for 1 h at 4 C. Supernatants (S1) were saved, while pellets
were resuspended in 6 vol of 50 mM Tris/HCl, pH 8.5, using a glass
dounce homogenizer (A and B: 2 · 20 strokes) and centrifuged
(100000 · g) for 1 h at 4 C. Both subsequent supernatants (cytosol)
and pellets (membrane-rich fraction) were combined and were used
for NQO2 enzymatic and 2-[125I]-MCANAT binding assays. Aliquots
of all preparations were stored at 80 C until use. Determination of
protein content was performed according to the Bradford method [32]
(Bio-Rad SA, Ivry-sur-Seine, France).
2.7. 2-[125I]-MCANAT binding assay
Protein preparations (40–500 lg/ml) were incubated in a 200 ll ﬁnal
volume with 0.2 nM of 2-[125I]-MCANAT (Amersham Pharmacia Bio-
tech) for 15 min at 4 C in 50 mM Tris/HCl, pH 8.5. Non-speciﬁc bind-
ing was determined with 10 lM of 2-iodo-MCANAT. The incubation
mixture (100 ll) was loaded on a 96 well plate gel ﬁltration method
using Sephadex G25 superﬁne (Amersham Pharmacia, Piscataway,
NJ) as chromatographic phase. The gel ﬁltration plate was then centri-
fuged at 1750 rpm for 25 s at 4 C and 30 ll of the 2-[125I]-MCANAT
bound to proteins was recovered for gamma radioactivity counting.
Data were expressed in fmol/mg of protein.
2.8. NQO2 ﬂuorescent enzymatic assay
The oxidoreduction reaction of NQO2 was realized at 25 C in
200 ll of 50 mM Tris/HCl, pH 8.5, in the presence or not of 100
lM of speciﬁc quinone reductase 1 (NQO1) inhibitor, i.e., dicoumarol
[33], using 100 lM menadione as substrate and 100 lM of BNAH as
co-substrate according to Nosjean et al. [17,21]. Brieﬂy, the decrease
of the intrinsic ﬂuorescence of BNAH (excitation at 340 nm with emis-
sion at 440 nM in a Polastar 96-well plate reader, BMG, Oﬀenburg,Germany) due to its oxidation in the presence of 100 lM menadione
was measured through a kinetic enzymatic method using the FLUO-
star Optima software (BMG, Oﬀenburg, Germany). Data were ex-
pressed in nmol/min/mg of protein.
2.9. QR1 assay
The QR1 enzymatic activity was measured using 200 lMmenadione
as substrate and 200 lM of b-nicotinamide adenine dinucleotide in its
reduced form (NADH) as co-substrate. The oxidoreduction reaction
was realized at 25 C in 200 ll of 25 mM Tris/HCl and 1 mM n-
octyl-b-D-glucopyranoside, pH 7.4. The enzymatic kinetic was meas-
ured, by following the decrease at 340 nm of the intrinsic ﬂuorescence
of the oxidized NADH (Polastar 96-well plate reader, BMG, Oﬀen-
burg, Germany) according to Zhou et al. [34].3. Results and discussion
Here, we report the construction of a mouse strain
(129sv · C57BL/6) in which the NQO2 gene was invalidated
(Fig. 1). Because we want to stabilize the genetic background
into a mouse strain having a recognized melatonin rhythm,
such as C57BL/6, and because this process will require several
months of breeding and crossing, we started with the biochem-
ical characterization of the ﬁrst KO animals, NQO2/. We
collected several tissues, including brain and kidneys from
the homozygous, heterozygous and wild type animals. The ge-
netic analysis of these animals conﬁrmed that they were de-
prived of the NQO2 gene (Fig. 1). Contrary to what might
be assumed, QR1 and NQO2 share similar catalytic properties,
in that they are both able to reduce menadione in the presence
of BNAH, the stable synthetic NRH analog (F. Vella, G. Fer-
ry and J.A. Boutin, unpublished). Nevertheless, QR1 is highly
sensitive to dicoumarol whereas NQO2 is not [23], permitting
to diﬀerentially characterize their respective activities. The tis-
sue homogenates from the homozygous mice do not support
any NQO2 activity, whereas they are able to catalyze the
QR1-mediated activities (i.e., menadione reduction in the pres-
ence of the co-substrate NADH and sensitive to dicoumarol
inhibition), see Table 1.
The 2-[125I]-MCANAT binding on mice organs has been de-
scribed by Nosjean et al . [17]. It is in the range of a few fmol
per mg of protein for mice brain and about 10 times more in
the kidney. This situation is similar to what is found in other
species, such as hamster and monkey, but not in dog [17].
We measured the same level of binding in similar conditions
in the membranes from brain and kidneys from wild-type mice.
Table 1 also documents the remarkable loss of melatonin MT3




The IUPHAR compendium for receptors stated that A re-
cent report identiﬁes anMT3 binding site in hamster as the en-
zyme QR2, as demonstrated by Nosjean et al. 2000] [10].
Indeed, the present data demonstrate unequivocally that the
putative binding site is exclusively this enzyme. No other
MT3 -like melatonin binding site can be detected when the tis-
sues are deprived of NRH-quinone oxidoreductase 2.
Whereas the physiological function of the MT3 binding site
has never been identiﬁed, the role of NQO2 is still a debate. In-
deed, by analogy with the QR1 enzyme, with which it shares
49% of its amino acid sequence [22], the literature stated that
it is a detoxifying enzyme belonging to the Phase II of the drug
metabolism and xenobiotic detoxiﬁcation processes. The data
reported on the previous NQO2 knock-out mice by Long
Table 1
Comparison of speciﬁc NQO2 enzymatic activity of kidney and brain protein preparations from wild type, heterozygous NQO2+/ and homozygous
NQO2/ mice






Kidney Brain Kidney Brain Kidney Brain
Dicoumarol (100 lM) Dicoumarol (100 lM)
Without With Without With
Wild type 14.4 ± 0.7 10.1 ± 0.9 7.0 ± 2.2 6.2 ± 2.0 6.4 ± 1.3 1.5 ± 0.1 2.9 ± 0.1 1.6 ± 0.1
Heterozygotes +/ 12.1 ± 0.1 5.3 ± 0.2 5.3 ± 1.6 4.2 ± 0.6 5.5 ± 0.6 0.5 ± 0.1 3.2 ± 0.2 1.6 ± 0.3
Homozygotes / 9.9 ± 4.9 0.3 ± 0.1 1.4 ± 0.8 0.8 ± 0.3 not detected not detected 2.6 ± 0.1 2.0 ± 0.0
NQO2 catalytic activity was measured using the standard ﬂuorescent assay, with BNAH (100 lM) and menadione (100 lM) as a co-substrate and
substrate, respectively. Binding was measured as described [17], using 2-[125I]-MCANAT. QR1 was measured using NADH (200 lM) as co-substrate
and menadione as substrate (200 lM) as described [34]. Data were obtained from three diﬀerent animals for each genotype. Activities were measured
at least twice per organ per animal. Results are given as means ± S.D.
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is rather a toxifying enzyme, since the menadione toxicity is
dramatically reduced in these knock-out animals [24].
The lack of a natural substrate reported for NQO2 (menadi-
one being a synthetic derivative of vitamin K) and of a natural
co-substrate (BNAH being a synthetic derivative of nicotina-
mide) is perplexing. While we obtained preliminary results
strongly suggesting that NQO2 recognizes the natural quinone
part of the mitochondrial respiratory chain, Coenzyme Q0,
(J.A. Boutin, F. Chatelain-Egger and G. Ferry, submitted
for publication), further work will be needed to better under-
stand the role of the enzyme in vivo.
Another perplexing relationship that needs to be docu-
mented is the connection between melatonin or 2-iodomelato-
nin, which have a strong aﬃnity for MT3 (280 and 8 nM,
respectively) in binding studies [17] and a poor inhibition
capacity for NQO2 activity (43 and 1 lM, respectively).
Although melatonin can be docked inside the catalytic site of
NQO2, its poor inhibition capacity remains at least unexpected
and still unclear. The fact that NQO2 could be a toxifying en-
zyme and that melatonin has protective eﬀects suggests that
NQO2-inhibition plays an important role. The high concentra-
tions used in vitro required for this protective eﬀect of melato-
nin [25,26] are compatible with the weak IC50 on NQO2.
Nevertheless, these concentrations are far from physiology. In-
deed, during the night, melatonin level is around 400 pmol/l in
plasma and can reach 10 nmol/l in the cerebrospinal ﬂuid, at
least in sheep [27]. According to a recent publication [28],
melatonin could be produced in lymphocytes at high concen-
trations, compatible with its documented anti-oxidant capacity
at pharmacological concentrations (i.e., in the 100 lM range).
At such concentrations, melatonin might inhibit the NQO2-
mediated toxifying process towards some of its natural sub-
strates, and therefore, melatonin could preserve some of the
activities of lymphocytes or other cellular components, during
the burst of oxidative processes seen in the blood during infec-
tions and fever events. Protective eﬀects of melatonin have also
been reported in diﬀerent animal models of ischemia [29,30]
with pharmacological doses around 10 mg/kg which give plas-
ma levels in rat over 1 lmol/l for at least 30 min [31], therefore
in the same range than the inhibition constant for the enzyme.
In the present report, we prove that MT3 and NQO2 are the
same molecular entities, by showing the absence of melatonin
binding site and NQO2 activity in tissues issued from NQO2-
KO mouse.Acknowledgements: The authors are grateful to Prof. M.C. Viaud-
Massard for the synthesis of 2-iodo-5-methoxycarbonylamino-N-ace-
tyltryptamine, to Dr. Roy Golsteyn for his help with the manuscript
and to Prof. Alain Ktorza for helpful advices.
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